Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)

• Alkermes plc recently reported interim results from a long‑term extension study showing its investigational orexin 2 receptor agonist alixorexton maintained clinically meaningful improvements in wakefulness, sleepiness, cognition and fatigue over 24 weeks in adults with narcolepsy types 1 and 2, with a generally acceptable safety profile.
• The data add weight to alixorexton’s potential as a differentiated, oral narcolepsy therapy as it advances through ongoing phase 3 Brilliance trials and benefits from Breakthrough Therapy and Orphan Drug designations.
• Next, we’ll examine how these sustained phase 2 extension results for alixorexton could influence Alkermes’ orexin franchise and broader investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Alkermes Investment Narrative Recap

To own Alkermes today, you have to believe its core neuroscience portfolio can support rising R&D spend while alixorexton evolves into a meaningful sleep‑medicine franchise. The new 24‑week extension data look directionally supportive for the orexin thesis, but they do not change the fact that the most important near‑term catalyst remains the Brilliance phase 3 readouts, and the biggest risk is still that late‑stage orexin trials fail to translate into approvable, clearly differentiated products.

Among recent announcements, the launch of the Brilliance phase 3 program in narcolepsy is most directly connected to this update. The long‑term extension results help frame expectations for durability and safety as Brilliance progresses, but the real inflection point is whether those registrational trials can meet their endpoints cleanly. With Q2 2026 results set for July 28, investors will also be watching how rising R&D for alixorexton is flowing through Alkermes’ P&L and cash generation.

Yet while orexin data look encouraging, investors should also be aware that...

Read the full narrative on Alkermes (it's free!)

Alkermes' narrative projects $2.1 billion revenue and $264.8 million earnings by 2029.

Uncover how Alkermes' forecasts yield a $47.69 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Bearish analysts were assuming revenue could fall to about US$1.3 billion by 2028 and earnings to roughly US$184 million, so if you worry about orexin competition and pricing pressure, this new alixorexton update might eventually shift that more pessimistic narrative in either direction.

Explore 5 other fair value estimates on Alkermes - why the stock might be worth 27% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com